Studies have shown that KRAS mutation is associated with worse overall survival in PD-L1 negative NSCLC, and this association is largely driven by comutations with STK11 and KEAP1, which are enriched in PD-L1 negative tumors (22). Here, KRAS is linked to non-small cell lung carcinoma.